John Climax PhD, DSc
Chairman & Chief Executive Officer

Professor John Climax co-founder of the world leading Clinical Research Organisation (CRO), ICON plc in 1990. He was the previous Chairman and CEO and current non-executive Director of ICON plc.  He is also founder of DS Biopharma, a dermatology biotech where he is Executive Chairman, and Afimmune, a biotech specialising in metabolic diseases where he is the CEO.

He is a founding member of Science Gallery International and Human Dignity Foundation. He is also affiliated with the boards of a number of private companies, Universities and foundations.

Professor Climax received his primary degree in Pharmacy from the University of Singapore, his Masters in Applied Pharmacology from the University of Wales and his Doctorate in Clinical Pharmacology from the University of Ireland. He was also awarded a Doctorate in Science by Trinity College Dublin.

He is Adjunct Professor of Pharmaceutics at the Royal College of Surgeons Ireland and Honorary Professor of Pharmacology and Pharmacy at National University of Singapore.  He is also an honorary fellow of St Hilda’s, University of Oxford.

Ronan Lambe PhD
Non-Executive Director

Dr. Lambe, is a co-founder of ICON plc, one of the world’s largest contract clinical research organizations. He has over 35 years of experience in the contract research industry.  Dr. Lambe attended the National University of Ireland where he received his Bachelor of Science degree in chemistry in 1959, his masters in biochemistry in 1962 and his PhD. in pharmacology in 1976.

Brendan Buckley PhD
Non-Executive Director

Professor Buckley was previously Chief Medical Officer at ICON plc and has 25+ years’ experience in clinical research as well as many years as a hospital consultant.

He was former chair of the HPRA Advisory Committee for Human Medicines & Irish member of the EMA COMP and previously Director of the European Collaborative Centre for Clinical Trials in Rare Diseases at University College Cork, where he continues to hold an Honorary Clinical Professorship.
Professor Buckley was also co-founder and SVP of Medical Affairs at Firecrest Clinical.

Jane Hollingsworth
Non-Executive Director

Jane is currently Executive Chair of Talee Bio, a gene therapy company focused on cystic fibrosis as well as diseases of the lung and Managing Partner of Militia Hill Ventures.

Jane is co-founder and former CEO of NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on diseases of the central nervous system which was sold to Teva in 2014. She also co-founded and served as Executive Vice President of Auxilium Pharmaceuticals (NASDAQ: AUXL), a biopharmaceutical company focused on urology which was sold to Endo Pharmaceuticals in 2015. Prior to launching and leading these two successful biopharmaceutical companies, Jane was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization.

Alan Cooke ACA
Non-Executive Director

Mr. Alan Cooke, has extensive experience in the healthcare and pharmaceutical market, and previously held positions of Chief Finanical Officer and Chief Executive Officer of the Trulife Group Limited.

Mr. Cooke has held a number of senior positions including President, Chief Operating Officer and Chief Financial Officer of Amarin Corporation plc. and Vice President, Global Strategic Planning of Elan Corporation plc. Mr. Cooke is Chairman of the Trinity College Institute of Neuroscience.

Leopoldo Zambeletti
Non-Executive Director

Mr. Zambeletti is a highly respected figure within the life sciences sector. During a 19 year career as an investment banker, he led the European Healthcare Investment team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years.

Since 2013 Mr Zambeletti has been an independent strategic advisor to life science companies on Merger and Acquisitions, out-licensing deals and financing strategy. He is a Non-Executive Director of Nogra Pharma, Advanced Accelerator Applications, Faron Pharmaceuticals, Summit Therapeutics plc. and an advisor and co-founder to the US medtech company Qardio.

He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St. Bartholomew, the Royal London and the London Chest Hospitals, and he is a founder of the cultural initiative 5×15 Italy. Mr Zambeletti started his career at KPMG as an accountant.

Mehar Manku PhD
Scientific Advisor

Dr. Mehar S. Manku has been active in lipid research for more than thirty years. During his lengthy career, Dr. Manku has authored some 250 scientific and technical papers and is the named inventor on 65 patents. Dr. Manku served for 35 years as an executive editor of the fatty acid journal Prostaglandin, Leukotrienes and Essential Fatty Acids. (PLEFAs). He was appointed editor in 2003 and held the position until late 2010, when he stood down to become Emeritus Editor. Recently, he was appointed Editor-in-Chief of Medical Hypotheses.

Dr. Manku worked in several research and development roles at Amarin Corporation from November 2004 to April 2010. Prior to Amarin, Dr. Manku worked in various scientific and technical roles at Scotia Pharmaceuticals Ltd and later at Laxdale Ltd (1979 – 2001).

Markus Weissbach MD, PhD
Chief Operating Officer and Medical Director

Dr Markus Weissbach has more than 25 years working experience in the international pharmaceutical, biotech and CRO industry. His previous appointments include Chief Medical Officer Europe at Novartis Vaccines and Diagnostics; Executive Chairman, CEO and President of Averion International Corp; President of ICON Clinical Research Plc., Europe; Director Clinical Research and Development at Takeda Euro R&D and International Medical Director at Knoll AG.

Dr. Weissbach has served as advisory/supervisory board member for companies such as CytoTools Biotech AG, Vasopharm, Cardiorentis, BernaBiotech, Sunesis, Merck KGaA, and Otsuka. He has been instrumental in the successful NDAs and market launch of several NCEs and biologics in different indications.

Dr. Weissbach is very well connected to academia & KOLs in different therapeutic areas such as, cardiology, vaccines, oncology, CNS, infectious and autoimmune diseases and has profound experience in dealing and negotiating with regulatory authorities in Europe and the USA.

Mark O'Neill ACA
Chief Financial Officer

Mr. O’Neill heads up the Finance division in DS Biopharma. Mr. O’Neill has a wealth of experience in bringing products to market and company financing. Prior to joining DS Biopharma, he held a number of senior financial and operational positions in organisations ranging from startup enterprises to large global established companies.

A Commerce graduate of University College Dublin and qualified Chartered Accountant with Deloitte, Mr. O’Neill also holds a Masters of Accounting from the Smurfit School of Business and a Diploma in Corporate Finance from the Institute of Chartered Accountants.

David Coughlan PhD
Chief Technical Officer

Dr. David Coughlan has over 15 years experience in pharmaceutical research and development. Dr. Coughlan joined DS Biopharma from Merrion Pharmaceuticals plc where he held a number of senior technical and management positions in the product development arena including Director of Formulations. Dr. Coughlan has significant experience in the management of a variety of product development programmes. He began his career with Élan Corporation plc.

Dr. Coughlan holds a B.Sc. in Pharmacy and PhD in Pharmaceutics from Trinity College Dublin, Ireland. He is a registered pharmacist and has authored numerous research papers and abstracts within the pharmaceutical field. He is a named inventor on a number of patents.